Patents Assigned to GlaxoSmithKline
  • Tricyclic benzoxaborole compounds and uses thereof
    Patent number: 10858376
    Abstract: Compounds of Formula II, wherein X is selected from chloro, fluoro, bromo and iodo, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or —CH(CH3)2; compositions containing them, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: December 8, 2020
    Assignees: GlaxoSmithKline Intellectual Property (No.2) Limited, Anacor Pharmaceuticals, Inc.
    Inventors: Michael Richard Kevin Alley, Vincent S. Hernandez, Jacob J. Plattner, Xianfeng Li, David Barros-Aguirre, Ilaria Giordano
  • Methods for adeno-associated viral vector production
    Patent number: 10858631
    Abstract: The invention relates to an adeno-associated virus (AAV) producer cell comprising nucleic acid sequences encoding: rep/cap gene; helper virus genes; and the DNA genome of the AAV vector particle, wherein the nucleic acid sequences are all integrated together at a single locus within the AAV producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that the nucleic acid vectors comprise nucleic acid sequences encoding: rep/cap gene, and helper virus genes. The invention also relates to uses and methods using the nucleic acid vectors in order to produce stable AAV packaging and producer cell lines.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: December 8, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Conrad Vink
  • Chemical compounds
    Patent number: 10851053
    Abstract: The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: December 1, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Anthony William Dean, Michael P. DeMartino, Hilary Schenck Eidam, Biswajit Kalita, Raghava Reddy Kethiri, Rajendra Kristam
  • Uses of parasite macrophage migration inhibitory factors
    Patent number: 10842859
    Abstract: This invention relates to compositions (e.g. vaccine compositions) which can be used to provide a subject with protective immunity against a parasite infection. The compositions comprise: (i) an immunologically effective amount of a nucleic acid (e.g. a nucleic acid-based vaccine) comprising a sequence which encodes a parasite macrophage migration inhibitory factor (MIF) antigen; (ii) a parasite MIF antigen; or (iii) an antibody which specifically binds to a parasite MIF antigen. The compositions may be used to treat infections and diseases caused by parasitic protozoans, such as a Plasmodium parasite, or parasitic helminths.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: November 24, 2020
    Assignees: Yale University, GlaxoSmithKline Biologicals SA
    Inventors: Richard Bucala, Andrew Geall
  • Pyridine dicarboxamide derivatives as bromodomain inhibitors
    Patent number: 10844015
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: November 24, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Etienne Levernier, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • PSEUDOMONAS ANTIGENS AND ANTIGEN COMBINATIONS
    Publication number: 20200360504
    Abstract: An effective Pseudomonas aeruginosa vaccine may require one or several antigenic components, and so various antigens of P. aeruginosa are identified for use in immunisation. These polypeptides may optionally be used in combination with other nosocomial antigens.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 19, 2020
    Applicants: GlaxoSmithKline Biologicals SA, Ospedale San Raffaele Srl
    Inventors: Vega MASIGNANI, Maria SCARSELLI, Roberto PETRACCA, Irene BIANCONI, Alessandra BRAGONZI, Beatriz ALCALA' FRANCO
  • Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
    Patent number: 10835592
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: November 17, 2020
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS
    Publication number: 20200325126
    Abstract: Disclosed are compounds having the formula: wherein Ra, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: April 5, 2017
    Publication date: October 15, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam Kenneth CHARNLEY, Robert Clifford Roback, Robert D. Gilbertson, Hakim Boukhalfa, Scott w. Imbus
  • NOPE for treatment of pathological muscle loss and weakness
    Patent number: 10799559
    Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 13, 2020
    Assignees: Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
  • Chemical compounds
    Patent number: 10793559
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 6, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Compounds Useful in HIV Therapy
    Publication number: 20200299309
    Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Richard M DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Substituted benzazinones as antibacterial compounds
    Patent number: 10781184
    Abstract: The present invention relates to LpxC antibacterial compounds of Formula (IA): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 22, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Qi Jin, Denise Teotico Pohlhaus, Jared T. Spletstoser
  • Conjugates comprising RIPK2 inhibitors
    Patent number: 10781205
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 22, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
  • TLR4 agonists and compositions thereof and their use in the treatment of cancer
    Patent number: 10765690
    Abstract: Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 8, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Christopher W. Cluff, Hua-Xin Gao
  • Toothbrush
    Patent number: 10758328
    Abstract: The present invention is concerned with a toothbrush, in particular an electric or otherwise driven toothbrush having a rotatable head, wherein the head incorporates arrays of bristle tufts, at least some of which extend substantially radially of the axis of rotation.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 1, 2020
    Assignee: GlaxoSmithKline Consumer Healthcare (UK) IP Limited
    Inventor: David Diamond
  • UspA2 protein constructs and uses thereof
    Patent number: 10745449
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 18, 2020
    Assignee: GlaxoSmithKline
    Inventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
  • Fusion proteins and combination vaccines comprising haemophilus influenzae Protein E and Pilin A
    Patent number: 10730917
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: August 4, 2020
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
    Patent number: 10730862
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 4, 2020
    Assignees: Yale University, Glaxosmithkline Intellectual Property Development, Cambridge Enterprise Limited University of Cambridge
    Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Denton Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
  • Compounds
    Patent number: 10730907
    Abstract: A compound of Formula (I) wherein Y1, Y2, X1, X2, R1, R2, R3, R4, R5, R6, R8, and R9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: August 4, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jerry Adams, Yiqian Lian
  • Template for a tufted curved surface
    Patent number: 10729231
    Abstract: The present invention provides a template for a tufted curved surface such as a hemispherical brush head for an electric toothbrush or the like, the template comprising a substrate having an upper surface adapted to carry one or more tufts of bristles such as to project outwardly from the upper surface, the substrate being shaped to be deformable between an expanded state in which the upper surface is substantially flat, and a collapsed state in which the upper surface is curved.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: August 4, 2020
    Assignee: GlaxoSmithKline Consumer Healthcare (UK) IP Limited
    Inventors: David Diamond, Jean Diamond